Primary Budd–Chiari Syndrome | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Portal vein thrombosis (PVT) refers to the development of a non-malignant obstruction of the
portal vein, its branches, its radicles, or a combination. This Review first provides a …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

DOACs emerged as a treatment of choice for secondary prevention of VTE and thrombosis
prophylaxis in AF in the general population, and may be an attractive alternative to VKAs in …

A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was
presented at the ISTH congress in 2021. We summarize here the main points of the lecture …

Abstract Purpose of Review Estimating and modifying thrombotic risk is currently the
mainstay of care for patients with polycythemia vera (PV) and essential thrombocythemia …

Splenomegaly is a hallmark of myelofibrosis, a debilitating haematological malignancy for
which the only curative option is allogeneic haematopoietic cell transplantation (HCT) …

Myeloproliferative neoplasms (MPNs) are the most common etiologies of primary splanchnic
vein thrombosis, present in almost forty percent of patients with Budd‐Chiari syndrome or …

Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress
has been made in better understanding the molecular pathogenesis and which patients may …

Background Patients with myeloproliferative neoplasms (MPNs), essential thrombocythemia
(ET), polycythemia vera (PV), and myelofibrosis (MF), have increased risk of cardiovascular …